Evidence map›Paper›PMID 42846631›Full record

ArticleExploration (Beijing, China)2026

A PD-L1 Nanobody-Engineered Synthetic RNA Virus Enhances Hepatocellular Carcinoma Immunotherapy by Interfering PCSK9 and Upregulating MHC-I.

Chuyu Huang, Yun Ye, Yi Guo, Guozheng Liao, Linyi Luo, Lingwen Ding, Yingling Miao, Linping Zhao, Yongchang Ouyang, Shiying Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Exploration (Beijing, China), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chuyu Huang *Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, the School of Pharmaceutical Sciences Guangzhou Medical University Guangzhou China.
Yun Ye *Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, the School of Pharmaceutical Sciences Guangzhou Medical University Guangzhou China.
Yi GuoGMU-GIBH Joint School of Life Sciences Guangzhou Medical University Guangzhou China.
Guozheng LiaoGMU-GIBH Joint School of Life Sciences Guangzhou Medical University Guangzhou China.
Linyi LuoGMU-GIBH Joint School of Life Sciences Guangzhou Medical University Guangzhou China.
Lingwen DingDepartment of Pathology, Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore.
Yingling MiaoGuangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, the School of Pharmaceutical Sciences Guangzhou Medical University Guangzhou China.
Linping ZhaoGuangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, the School of Pharmaceutical Sciences Guangzhou Medical University Guangzhou China.
Yongchang OuyangGMU-GIBH Joint School of Life Sciences Guangzhou Medical University Guangzhou China.
Shiying LiGuangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, the School of Pharmaceutical Sciences Guangzhou Medical University Guangzhou China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is characterized by low expression of major histocompatibility complex class I (MHC-I), which significantly limits the efficacy of immunotherapy. In this work, bioinformatic analysis finds that elevated PCSK9 in HCC correlates with reduced T cell activity and poor prognosis. Based on these discoveries, a PD-L1 nanobody-engineered synthetic RNA virus (αPDL1-VLPs/shPCSK9) is fabricated to inhibit PCSK9, thereby restoring MHC-I expression to enhance HCC immunotherapy. The αPDL1-VLPs/shPCSK9 is produced using MS2 virus-like particles (VLPs) in

Indexed as

gene therapyimmunotherapyMS2 virus‐like particles

Identifiers

PMID42846631
PMCPMC13643016

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.